Mark G. Lebwohl is an American dermatologist and author who is Professor and Chairman Emeritus of the Kimberly and Eric J. Waldman Department of Dermatology and the Dean for Clinical Therapeutics at the Icahn School of Medicine at Mount Sinai in New York City.[1][2]
Lebwohl's books include the book on dermatologic therapy, Treatment of Skin Disease (ISBN0323036031), as well as Atlas of the Skin and Systemic Disease (ISBN044306539X). He has authored more than 500 publications,[3][4] multiple book chapters and has been named as one of New York Magazine’s “Best Doctors” every year since the inception of the annual list.[5][6] Dr. Brian S. Kim is director of a Center for Neuroinflammation and Sensation named in Mark Lebwohl's honor at Icahn School of Medicine at Mount Sinai.
In 1983, he was made assistant professor of dermatology at Mount Sinai. In 1997, he was named Chairman of the Department[3] which, under his leadership, has been at the forefront of the management of psoriasis.[7]
Lebwohl was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease.[7] He was also the first to use immunomodulators (imiquimod) to treat precancerous skin lesions;[8][9] the first to use topical calcineurin inhibitors to treat psoriasis;[10] and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light.[11][12][13]
Lebwohl has served as president of the New York Dermatological Society, the Manhattan Dermatologic Society, and the New York State Society of Dermatology, and as chairman of the Dermatology Section of the New York Academy of Medicine. He served as chairman of the National Psoriasis Foundation's medical board[14] chairman of the Psoriasis Task Force of the American Academy of Dermatology (AAD) and was a member of the Scientific Assembly Council. He chaired the academy's summer meeting in 2001 in California and the AAD annual meeting in Washington, D.C. in 2004. He was elected to the Board of Directors of the AAD for 2010–2014. In 2020, he was elected to the board of the American Skin Association.[15][16]
2003 The Jacobi medallion, Mount Sinai Medical Center
2003 British Medical Association Medical Books Competition[20]
Highly commended electronic media award for Treatment of Skin Disease, PDA version.
2005 Distinguished Service Award, American Dermatological Association
2006 Winner, The Society of Authors and the Royal Society of Medicine Book Awards for New Edition of an Edited Book, Treatment of Skin Disease: Comprehensive Therapeutic Strategies (2nd edition)[21]
Lebwohl is on the editorial board of the Journal of the American Academy of Dermatology and was the editor of the Dermatology Section of Scientific American Medicine, now called ACP Medicine. He is a founding editor of Psoriasis Forum and was medical editor of the bulletin of the National Psoriasis Foundation, Psoriasis Advance.[13][22][23]
Lebwohl M, Heymann WR, Berth-Jones J, Coulson I, editors. Treatment of Skin Disease, 3rd edition (2010). London, Mosby 2nd edition (2006) 1st edition (2002) Also published in electronic versions and in Polish and Portuguese. ISBN0-7020-3121-6
Koo JM, Lebwohl MG, Lee CS, editors. Mild-to-Moderate Psoriasis 2nd edition(2008). New York, Informa Healthcare 1st edition (2006) ISBN1-4200-8860-2
Lebwohl MG. The Skin and Systemic Disease: A Color Atlas and Text, 2nd edition (2004). New York, Churchill Livingstone Also published in French. ISBN0-443-06539-X
Lebwohl M. Atlas of the Skin and Systemic Disease (1995). New York, Churchill Livingstone ISBN0-443-06539-X
Lebwohl M, editor. Difficult Diagnoses in Dermatology (1988). New York, Churchill Livingston ISBN0-443-08460-2
Lebwohl M, author, treatment of Skin Disease: Comprehensive Therapeutic Strategies (2013), Saunders; 4 edition, ISBN0-702-03375-8
Roenigk, Henry H.; Auerbach, Robert; Maibach, Howard; Weinstein, Gerald; Lebwohl, Mark (March 1998). "Methotrexate in psoriasis: Consensus conference". Journal of the American Academy of Dermatology. 38 (3): 478–485. doi:10.1016/s0190-9622(98)70508-0. PMID9520032.
Papp, Kim A; Langley, Richard G; Lebwohl, Mark; Krueger, Gerald G; Szapary, Philippe; Yeilding, Newman; Guzzo, Cynthia; Hsu, Ming-Chun; Wang, Yuhua; Li, Shu; Dooley, Lisa T; Reich, Kristian (May 2008). "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)". The Lancet. 371 (9625): 1675–1684. doi:10.1016/S0140-6736(08)60726-6. PMID18486740. S2CID22327170.
Kalb, Robert E.; Strober, Bruce; Weinstein, Gerald; Lebwohl, Mark (May 2009). "Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference". Journal of the American Academy of Dermatology. 60 (5): 824–837. doi:10.1016/j.jaad.2008.11.906. PMID19389524.
Lebwohl, Mark; Ellis, Charles; Gottlieb, Alice; Koo, John; Krueger, Gerald; Linden, Kenneth; Shupack, Jerome; Weinstein, Gerald (September 1998). "Cyclosporine consensus conference: With emphasis on the treatment of psoriasis". Journal of the American Academy of Dermatology. 39 (3): 464–475. doi:10.1016/S0190-9622(98)70325-1. PMID9738783.
Lebwohl, Mark; Bagel, Jerry; Gelfand, Joel M.; Gladman, Dafna; Gordon, Kenneth B.; Hsu, Sylvia; Kalb, Robert E.; Kimball, Alexa Boer; Korman, Neil J.; Krueger, Gerald G.; Mease, Philip; Morison, Warwick L.; Paller, Amy; Pariser, David M.; Ritchlin, Christopher; Strober, Bruce; Van Voorhees, Abby; Weinstein, Gerald D.; Young, Melodie; Horn, Liz (January 2008). "From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis". Journal of the American Academy of Dermatology. 58 (1): 94–105. doi:10.1016/j.jaad.2007.08.030. PMID17980456.
Zachariae, Claus; Gordon, Kenneth; Kimball, Alexandra B.; Lebwohl, Mark; Blauvelt, Andrew; Leonardi, Craig; Braun, Daniel; McKean-Matthews, Missy; Burge, Russel; Cameron, Gregory (August 2018). "Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis". Journal of the American Academy of Dermatology. 79 (2): 294–301.e6. doi:10.1016/j.jaad.2018.03.047. PMID29653208. S2CID4846284.
Mikhaylov, Daniela; Pavel, Ana; Yao, Christopher; Kimmel, Grace; Nia, John; Hashim, Peter; Vekaria, Anjali S.; Taliercio, Mark; Singer, Giselle; Karalekas, Rachel; Baum, Danielle; Mansouri, Yasaman; Lebwohl, Mark G.; Guttman-Yassky, Emma (11 November 2018). "A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata". Archives of Dermatological Research. 311 (1): 29–36. doi:10.1007/s00403-018-1876-y. PMID30417279. S2CID53250523.
Menter, Alan; Gelfand, Joel M.; Connor, Cody; Armstrong, April W.; Cordoro, Kelly M.; Davis, Dawn M.R.; Elewski, Boni E.; Gordon, Kenneth B.; Gottlieb, Alice B.; Kaplan, Daniel H.; Kavanaugh, Arthur; Kiselica, Matthew; Kivelevitch, Dario; Korman, Neil J.; Kroshinsky, Daniela; Lebwohl, Mark; Leonardi, Craig L.; Lichten, Jason; Lim, Henry W.; Mehta, Nehal N.; Paller, Amy S.; Parra, Sylvia L.; Pathy, Arun L.; Prater, Elizabeth Farley; Rahimi, Robert S.; Rupani, Reena N.; Siegel, Michael; Stoff, Benjamin; Strober, Bruce E.; Tapper, Elliot B.; Wong, Emily B.; Wu, Jashin J.; Hariharan, Vidhya; Elmets, Craig A. (June 2020). "Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies". Journal of the American Academy of Dermatology. 82 (6): 1445–1486. doi:10.1016/j.jaad.2020.02.044. PMID32119894.
